Who
Simon Read
Director
Company insider
Files Form 4 as: Director, Dianthus Therapeutics; Chief Scientific Officer, Ra Pharmaceuticals.
In numbers
- Trades disclosed
- 62
- Buys
- 0
- Sells
- 9
- Bought
- $0
- Sold
- $3.8M
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 1 Feb 2017
- Last trade
- 19 Aug 2026
- Last filed
- 19 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 19 Aug 2026filed 19 Aug 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Code M | $51K2,778 at $18.36 | filing |
| 19 Aug 2026filed 19 Aug 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Sold | $327K2,778 at $117.55 | filing |
| 19 Aug 2026filed 19 Aug 2026 | DNTH Dianthus Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,778 at $0.00 | filing |
| 19 Aug 2026filed 19 Aug 2026 | DNTH Dianthus Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,778 at $0.00 | filing |
| 19 Aug 2026filed 19 Aug 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Code M | $51K2,778 at $18.36 | filing |
| 19 Aug 2026filed 19 Aug 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Sold | $327K2,778 at $117.55 | filing |
| 10 Aug 2026filed 11 Aug 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Code M | $51K2,777 at $18.36 | filing |
| 10 Aug 2026filed 11 Aug 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Sold | $7,49870 at $107.11 | filing |
| 10 Aug 2026filed 11 Aug 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Sold | $80K737 at $108.17 | filing |
| 10 Aug 2026filed 11 Aug 2026 | DNTH Dianthus Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,777 at $0.00 | filing |
| 10 Aug 2026filed 11 Aug 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Sold | $91K831 at $108.95 | filing |
| 10 Aug 2026filed 11 Aug 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Sold | $30K272 at $109.96 | filing |
| 10 Aug 2026filed 11 Aug 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Sold | $52K470 at $111.05 | filing |
| 10 Aug 2026filed 11 Aug 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Sold | $44K397 at $111.77 | filing |
| 10 Aug 2026filed 11 Aug 2026 | DNTH Dianthus Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,777 at $0.00 | filing |
| 10 Aug 2026filed 11 Aug 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Code M | $51K2,777 at $18.36 | filing |
| 10 Aug 2026filed 11 Aug 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Sold | $7,49870 at $107.11 | filing |
| 10 Aug 2026filed 11 Aug 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Sold | $80K737 at $108.17 | filing |
| 10 Aug 2026filed 11 Aug 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Sold | $91K831 at $108.95 | filing |
| 10 Aug 2026filed 11 Aug 2026 | DNTH Dianthus TherapeuticsBiotechnology | SEC FORM 4 Sold | $30K272 at $109.96 | filing |
News
Analyzing Connect Biopharma (NASDAQ:CNTB) & Dianthus Therapeutics (NASDAQ:DNTH)DNTH · tickerreport.com · 22 Oct 2026Dianthus Therapeutics Recognized Among Fortune's 2026 Best Workplaces In BioPharmaDNTH · manilatimes.net · 13 Oct 2026
0 headlines in the last 90 days name Simon Read; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.